Management with colistin
2010

Management with Colistin

publication

Author Information

Author(s): Gupta Sachin, Govil Deepak, Kakar Prem N., Prakash Om, Arora Deep, Das Shibani, Govil Pradeep, Malhotra Ashima

Primary Institution: Max Super Speciality Hospital

Conclusion

Colistin is becoming a standard adjuvant therapy for Ventilator Associated Pneumonia with lower toxicity than previously reported.

Supporting Evidence

  • Colistin is resistant to certain bacterial species.
  • Aerosolization of colistin is becoming standard for treating lung infections.
  • Bronchospasm is less common than previously thought when using colistin.
  • Recent literature shows colistin has lower toxicity than older reports.

Takeaway

Colistin can help treat lung infections in patients on ventilators, and it seems to be safer now than it used to be.

Methodology

Colistin is administered through ultrasonic nebulizers to maximize lung concentration.

Potential Biases

Theoretical neurological side effects are mentioned, but recent data suggest lower toxicity.

Limitations

No data are available for dose adjustment for nebulization in renal disease.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication